AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12401613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg/kg (Group E70)
Number of subjects: 176
Study 12401613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 110 microg/kg (Group E110)
Number of subjects: 176
Study 12401613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 150 microg/kg (Group E150)
Number of subjects: 176
Study 12401613 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Group P)
Number of subjects: 176
Study 10201104 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and negative reinforcement with concurrent choice options including parent attention and preferred toys
Number of subjects: 2
Study 10201104 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of parent instructions in choice areas with parent attention
Number of subjects: 2
Study 7776180 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading combined with coloring pictures
Number of subjects: 3
Study 7776180 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity identified as primary during initial engagement
Number of subjects: 3
Study 7776180 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple input activities identified as alternatives
Number of subjects: 3
Study 7776180 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses connected to identified activity during initial engagement
Number of subjects: 3
Study 1971862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 127
Study 1971862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 6991164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous androstenedione administration
Number of subjects: 40
Study 6991164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31050709 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT-inhibitors in combination with first-line chemotherapy
Number of subjects: 0
Study 28846543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori stent (biodegradable polymer-coated biolimus-eluting)
Number of subjects: 2468
Study 28846543 — intervention group
Group type: COMPARATOR
Intervention: CYPHER stent (durable polymer-coated sirolimus-eluting)
Number of subjects: 2468
Study 26457343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.4 mg
Number of subjects: 128
Study 26457343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 23292882 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 24
Study 23292882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21302161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (100 ng/mL plasma)
Number of subjects: 14
Study 21302161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19695076 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (N = 15) - participated in social activity immediately
Number of subjects: 91
Study 19695076 — intervention group
Group type: COMPARATOR
Intervention: Group C (N = 60) - did not participate in social activity
Number of subjects: 91
Study 16904123 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to novel words in meaningful text or in isolation; number of exposures manipulated (once, twice, or four times)
Number of subjects: 0
Study 15087413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise intervention (45 min, 5 days/week)
Number of subjects: 173
Study 15087413 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study 11534310 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (group D, n = 31)
Number of subjects: 63
Study 11534310 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 32)
Number of subjects: 63
Study 10806672 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix IN
Number of subjects: 607
Study 10806672 — intervention group
Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 607
Study 7841427 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 520
Study 7841427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg
Number of subjects: 520
Study 7841427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg
Number of subjects: 520
Study 3394914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (10 mg) with oral diazepam (0.2 mg/kg)
Number of subjects: 6
Study 3394914 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam (0.2 mg/kg) alone
Number of subjects: 6
Study 29677629 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate intensity physical training (2 sessions per week for 26 weeks)
Number of subjects: 60
Study 29677629 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study 25790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) therapy
Number of subjects: 32
Study 23940250 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of heaters in homes
Number of subjects: 309
Study 21564138 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol
Number of subjects: 78
Study 21564138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 18279921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (5 metered doses of 10% lidocaine)
Number of subjects: 144
Study 18279921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (10 mL)
Number of subjects: 144
Study 18279921 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricating gel (10 mL)
Number of subjects: 144
Study 17702020 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 116
Study 17702020 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 116
Study 17702020 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 116
Study 15491234 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 55
Study 15491234 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 55
Study 11165579 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study 11165579 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 55
Study 9644281 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical coordination mode
Number of subjects: 7
Study 9644281 — intervention group
Group type: COMPARATOR
Intervention: Asymmetrical coordination mode
Number of subjects: 7
Study 8195906 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage screening
Number of subjects: 7856
Study 8195906 — intervention group
Group type: COMPARATOR
Intervention: Two-stage screening
Number of subjects: 7856
Study 3069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized 0.5% bupivacaine and 1 in 200,000 adrenaline (group 2)
Number of subjects: 24
Study 3069003 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (group 1)
Number of subjects: 24
Study 25760652 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned labels
Number of subjects: 96
Study 25760652 — intervention group
Group type: COMPARATOR
Intervention: Current labels
Number of subjects: 96
Study 26414004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for 12 weeks
Number of subjects: 52
Study 26414004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26414004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 52
Study 26414004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 52
Study 24018240 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-8539 (30 mg)
Number of subjects: 435
Study 24018240 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-8539 (100 mg)
Number of subjects: 435
Study 24018240 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-8539 (300 mg)
Number of subjects: 435
Study 24018240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 24018240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg)
Number of subjects: 435
Study 24018240 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-8539 (30, 100, 300 mg)
Number of subjects: 435
Study 22425471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6mg)
Number of subjects: 12
Study 22425471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond and halogen light
Number of subjects: 72
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond and LED
Number of subjects: 72
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho and halogen light
Number of subjects: 72
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho and LED
Number of subjects: 72
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho, without acid and halogen light
Number of subjects: 72
Study 20379684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho, without acid and LED
Number of subjects: 72
Study 20379684 — intervention group
Group type: COMPARATOR
Intervention: Halogen light
Number of subjects: 72
Study 20379684 — intervention group
Group type: COMPARATOR
Intervention: LED
Number of subjects: 72
Study 18356686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg) + Propranolol (80 mg)
Number of subjects: 56
Study 18356686 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Aspirin (100 mg)
Number of subjects: 56
Study 18356686 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Propranolol (80 mg)
Number of subjects: 56
Study 18356686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16238986 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program
Number of subjects: 180
Study 12402619 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (40-70 subcutaneous units/kg weekly)
Number of subjects: 45
Study 10089839 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rate‐smoothing algorithm
Number of subjects: 240
Study 10089839 — intervention group
Group type: COMPARATOR
Intervention: Inactive rate‐smoothing algorithm
Number of subjects: 240
Study 7538520 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.03%
Number of subjects: 285
Study 2213869 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful life events experienced during each of 6 years of follow-up
Number of subjects: 12866
Study 2213869 — intervention group
Group type: COMPARATOR
Intervention: Type A behavior
Number of subjects: 12866
Study 160741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cyproterone acetate + 0.05 mg ethinyl estradiol (Diane)
Number of subjects: 0
Study 31348806 — intervention group
Group type: EXPERIMENTAL
Intervention: OS-Citicoline 500 mg/day for 6 months
Number of subjects: 36
Study 31348806 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NN Group)
Number of subjects: 36
Study 31348806 — intervention group
Group type: EXPERIMENTAL
Intervention: OS-Citicoline 500 mg/day for 6 months followed by 3 months wash-out (NC Group)
Number of subjects: 36
Study 28238601 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC4V vaccine
Number of subjects: 188
Study 28238601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 26546896 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise for 30 minutes a day, three days a week for six weeks
Number of subjects: 26
Study 26546896 — intervention group
Group type: COMPARATOR
Intervention: Control group received education and maintained normal life
Number of subjects: 26
Study 23683140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast switching to atomoxetine (ATX) over 2 weeks
Number of subjects: 111
Study 23683140 — intervention group
Group type: COMPARATOR
Intervention: Slow switching to atomoxetine (ATX) over 10 weeks
Number of subjects: 111
Study 21311495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided umbilical catheter placement
Number of subjects: 0
Study 21311495 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of umbilical catheter placement
Number of subjects: 0
Study 18722084 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage as an intervention in the clinical trial sample
Number of subjects: 0
Study 18722084 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17535313 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education plus contingency management behavioral protocol
Number of subjects: 77
Study 17535313 — intervention group
Group type: COMPARATOR
Intervention: Control group (received instruction on PEF monitoring only)
Number of subjects: 77
Study 17535313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 77
Study 15572094 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive surveillance regimen
Number of subjects: 985
Study 15572094 — intervention group
Group type: COMPARATOR
Intervention: Less intensive surveillance regimen
Number of subjects: 985
Study 11443167 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 179
Study 11443167 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 179
Study 9532986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day from 36 weeks of gestation until delivery
Number of subjects: 63
Study 9532986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9532986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day
Number of subjects: 63
Study 8032955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 and leucovorin (LV) 500 mg/m2 intravenously weekly for 6 weeks followed by 2 weeks' rest and interferon alfa-2b 8 million units (MU) subcutaneously tiw with no rest period.
Number of subjects: 17
Study 8032955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) with interferon alfa-2b at doses of 1, 3, 5, 8, or 10 MU.
Number of subjects: 17
Study 8032955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and leucovorin (LV) with interferon alfa-2b.
Number of subjects: 17
Study 2558691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin (10,000 AXa Institut Choay units)
Number of subjects: 8
Study 2558691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin (various dosages)
Number of subjects: 8
Study 2558691 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 8
Study 2558691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin
Number of subjects: 8
Study 270473 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 6-mercaptopurine (6-MP), vincristine, prednisone, and intrathecal methotrexate (MTX)
Number of subjects: 32
Study 270473 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional immunotherapy with BCG or allogenic myeloblasts
Number of subjects: 32
Study 270473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of polychemotherapy and immunotherapy with neuraminidase-treated myeloblasts
Number of subjects: 32
Study 270473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara-C infusion therapy combined with 3 days of daunorubicin and inoculation with methanol extraction supernatant of tubercle bacilli
Number of subjects: 32
Study 31652237 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training in the fed state (after consuming breakfast)
Number of subjects: 25
Study 31652237 — intervention group
Group type: COMPARATOR
Intervention: Endurance-type exercise training in the fasted state
Number of subjects: 25
Study 31652237 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-type exercise training (both groups)
Number of subjects: 25
Study 30690645 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 277
Study 30690645 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study 27881565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 or 100 mg daily)
Number of subjects: 2539
Study 27881565 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2539
Study 26017715 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 1.5 microgram
Number of subjects: 60
Study 26017715 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 5 microgram
Number of subjects: 60
Study 26017715 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study 26017715 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia alone
Number of subjects: 60
Study 23975881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23975881 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0
Study 23975881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 22166736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track surgery protocol
Number of subjects: 0
Study 22166736 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimen
Number of subjects: 0
Study 19549403 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG regimen (low-dose cytarabine and aclarubicin with G-CSF)
Number of subjects: 50
Study 19549403 — intervention group
Group type: COMPARATOR
Intervention: Control group (anthracycline in combination with cytarabine)
Number of subjects: 50
Study 16839819 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counselling intervention
Number of subjects: 200
Study 15189174 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure (CRF) patients
Number of subjects: 315
Study 15189174 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure (CRF) patients with tHcy ≥ 25 micromol/L
Number of subjects: 315
Study 15189174 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched healthy controls
Number of subjects: 315
Study 11307132 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 43
Study 11307132 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 43
Study 9395759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 161
Study 9395759 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 161
Study 7947368 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (200 mg daily)
Number of subjects: 53
Study 7947368 — intervention group
Group type: COMPARATOR
Intervention: nifedipine (40 mg daily)
Number of subjects: 53
Study 3030900 — intervention group
Group type: EXPERIMENTAL
Intervention: ispaghula husk 10 g
Number of subjects: 10
Study 3030900 — intervention group
Group type: EXPERIMENTAL
Intervention: ispaghula husk 20 g
Number of subjects: 10
Study 3030900 — intervention group
Group type: EXPERIMENTAL
Intervention: ispaghula husk 30 g
Number of subjects: 10
Study 3030900 — intervention group
Group type: EXPERIMENTAL
Intervention: ispaghula husk 10 g, 20 g, 30 g (in random order)
Number of subjects: 10
Study 31811498 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy, administered three times a week during RT.
Number of subjects: 33
Study 28597973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 4 g/day OM3‐CA
Number of subjects: 24
Study 28597973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28597973 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day OM3‐CA
Number of subjects: 24
Study 27738330 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL-6 levels
Number of subjects: 393
Study 27738330 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum CRP levels
Number of subjects: 393
Study 27738330 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels in patients with BRAF mutation
Number of subjects: 393
Study 25630242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue
Number of subjects: 8
Study 23312683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow nasal prongs therapy with room air (1 L/min)
Number of subjects: 78
Study 23312683 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing in room air (control)
Number of subjects: 78
Study 20698734 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily salt intake (18.01 g/day)
Number of subjects: 1970
Study 20698734 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake in normal weight individuals
Number of subjects: 1970
Study 18390024 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits with environmental remediation (n = 153)
Number of subjects: 281
Study 18390024 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits only (n = 128)
Number of subjects: 281
Study 18390024 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (n = 115)
Number of subjects: 281
Study 16869848 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise on a stationary bicycle ergometer
Number of subjects: 40
Study 16869848 — intervention group
Group type: COMPARATOR
Intervention: Cognitive distraction task (paced visual serial addition task, PVSAT)
Number of subjects: 40
Study 14597872 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (PAC) 100 mg/m2 infused over 1 hour
Number of subjects: 121
Study 14597872 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PAC) 100 mg/m2 infused over 3 hours
Number of subjects: 121
Study 15136112 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified hMG
Number of subjects: 0
Study 15136112 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 0
Study 10022422 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 0
Study 10022422 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0